Clinical Research On Shenfu Injection Decreasing The Toxicities Of Gemcitabine Plus Cisplatin For Treating Advanced Non-Small Cell Lung Cancer

Objective: To observe the therapeutic effect of Shenfu Injection (SHF) decreasing the toxicities and improving the quality of life in the patients with advanced Non-Small Cell Lung Cancer (NSCLC) with Gemcitabine plus Cisplatin(GP) .Methods: The patients with NSCLC were given at least two cycles of GP regimen: 1250mg/m~2 of Gemcitabine on days 1 and 8 and 70mg/m~2 of Cisplatin on day 2 were administered every 3 weeks. One cycle combined with Shenfu Injection (SHF+GP):SHF 60ml+0.9%NS 250ml, ivd, qd, for 10 days; GP regimen was administered from the fourth day. Another cycle was only given with GP regimen. All patients were randomly divided into two groups: 18 patients in the SHF first-treat group , in which SHF+GP was given in the first cycle , and in the second cycle only GP was given; 16 patients in the SHF second-treat group, in which only GP was given in the first cycle and SHF+GP was given in the second cycle. The toxicity, adverse effect, symptomatic relief, quality of life and the immunological function were documented and compared. Results: The major toxicities of GP regimen were hematlogical toxicity and digestive toxicity. The hematlogical toxicity were World Health Organization grade 1-3 neutropenia and thrombocytopenia. The digestive toxicities were grade 1-4 vomiting and grade 1-2 constipation. Among 34 patients, the hematological toxicity of SHF+GP is lower than GP (P<0. 01). The hematlogical toxicity of SHF+GP was lower than the single GP regimen(P<0. 01) in the SHF first-treat group but was similar to the single GP(P>0. 05) in the SHF second-treat group. About the digestive toxicity, vomiting of SHF+GP was lower than GP both in two groups (P<0. 01, P<0. 05). After treatment, both the quality...